Sagimet Biosciences Inc. Series A Common Stock (SGMT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Sagimet Biosciences Inc. Series A Common Stock.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 269.0% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.28 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.26 | – | 0 | – | – | -11 | -11 |
| 2025: Q1 | -0.30 | – | 0 | – | – | -15 | -15 |
| 2025: Q2 | -0.17 | – | 0 | – | – | -9 | -9 |
| 2025: Q3 | -0.21 | – | 0 | – | – | -10 | -10 |
| 2025: Q4 | -0.16 | – | 0 | – | – | -12 | -12 |
| 2026: Q1 | -0.17 | – | 0 | – | – | -9 | -9 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Sagimet Biosciences Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt neuartige Therapeutika namens Fettsäuresynthase-(FASN-)Inhibitoren zur Behandlung von Erkrankungen, die aus gestörten metabolischen und fibrotischen Signalwegen resultieren, in den USA.
| Employees | 16 |
|---|---|
| Headquarters | San Mateo, CA |
| Website | sagimet.com |
| IPO Date | 14. Jul 2023 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David A. Happel | CEO, President & Director | 1962 |
| Elizabeth Rozek Esq., J.D. | Chief Legal & Administrative Officer | 1972 |
| Urs Greber Ph.D. | Co-Founder | – |
| Lucas Pelkmans Ph.D. | Co-Founder | – |
| Thierry Chauche | CFO & Principal Accounting Officer | 1976 |
| Marie O'Farrell Ph.D. | Chief Scientific Officer | – |
| Robert D'Urso | Senior Vice President of New Products | – |
| Andreas Grauer M.D. | Chief Medical Officer | 1961 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 20. Jul 2026 | Happel David | President & CEO | Sell | 64,051 | 7.76 | 497,068 |
| 20. Jul 2026 | Rozek Elizabeth | Chief Legal & Admin. Officer | Sell | 10,545 | 7.76 | 81,832 |
| 20. Jul 2026 | Kemble George | Director | Sell | 18,844 | 7.46 | 140,529 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.